Roth Capital upgraded I-Flow (IFLO) to strong buy from buy.
Analyst Jason Kroll says he thinks the adoption of I-Flow's ON-Q post-operative pain pump is beginning to accelerate. He says sales are accelerating faster than he predicted. He thinks I-Flow could grow at a compound annual growth rate of 31% over the next three years, driven mainly by the ON-Q family of products.
Kroll thinks there's several factors including the publication of numerous clinical studies, the implementation of effective sales, and marketing strategy playing a significant role in driving the adoption of ON-Q. He raised his 2-cent 2003 loss estimate to 1 cent earnings per share, and upped the 6 cents 2004 earnings per share estimate to 10 cents earnings per share. He also raised the $6 target to $10.